Mark Schoenberg Sells 4,551 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN opened at $11.64 on Thursday. UroGen Pharma Ltd. has a one year low of $9.78 and a one year high of $20.70. The company has a 50-day simple moving average of $11.10 and a 200-day simple moving average of $12.61. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the prior year, the company earned ($0.68) earnings per share. As a group, equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. RTW Investments LP lifted its holdings in shares of UroGen Pharma by 6.5% during the third quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after purchasing an additional 230,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in UroGen Pharma by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock valued at $17,032,000 after buying an additional 21,072 shares during the period. State Street Corp raised its position in UroGen Pharma by 5.9% during the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after buying an additional 42,907 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after acquiring an additional 34,248 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in shares of UroGen Pharma in the third quarter valued at about $5,080,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of research reports. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, January 23rd. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Oppenheimer reissued an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.